This year's flu season kicked off unusually early, with H1N1 dominating and the West Coast hit hardest. The core clinical approach hasn't changed, but the early start means many patients haven't been vaccinated yet — putting more pressure on timely testing and antiviral decisions. Experts say early treatment for high-risk patients remains key, and everyone should get vaccinated now.
This flu season is off to an unusually early start, with H1N1 accounting for 96% of subtyped influenza A viruses and the West Coast seeing the most activity. CDC data from the week ending October 10 showed 5% of clinical lab flu tests coming back positive — up from 3.9% the prior week. Pediatric ED visits are climbing, and experts believe the back-to-school season may have accelerated the spread. A hemagglutinin mutation called G155E, present in ~75–80% of recent H1N1 strains, is thought to be a key driver by exploiting gaps in population immunity.
Despite the early timing, the fundamental clinical approach hasn't shifted. The biggest concern is that many patients haven't yet been vaccinated, expecting the usual December–January peak. Experts urge anyone unvaccinated to get the shot now, and stress that antivirals work best when started within 48 hours of symptom onset — but most patients seek care only around days 5–7.
Key Takeaways:
Why it matters: An early flu season has caught many patients unvaccinated, and clinicians must weigh antiviral trade-offs carefully — especially for children and high-risk adults — while tracking local severity data, not just case counts.
